Floatz logo

Silybin

Newly Diagnosed

Fujian Medical University Union HospitalPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Newly Diagnosed cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 4BB
cc-5013
The First Affiliated Hospital of Soochow University
Phase 4BB
Bortezomib
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
The First Affiliated Hospital of Soochow University
Phase 4BB
Daunorubicin
Fujian Medical University Union Hospital
Phase 4B

View all 34 →

Same molecule, other indications

Silybin is also rated in:

fibrotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →
chemotherapy-induced toxicityDormant
B
Indicative ·
62 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →